MorphoSys Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St

November 18, 2023

MorphoSys (ETR:MOR) Third Quarter 2023 Results

Key Financial Results

Revenue: €63.8m (down 33% from 3Q 2022).
Net loss: €119.6m (loss narrowed by 2.7% from 3Q 2022).
€3.50 loss per share (improved from €3.60 loss in 3Q 2022).

earnings-and-revenue-growth — XTRA:MOR Earnings and Revenue Growth November 18th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

MorphoSys Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 88%.

Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.

Performance of the German Biotechs industry.

The company's shares are down 24% from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with MorphoSys.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.